Bellco Capital

Bellco Capital is a Los Angeles-based, privately held investment firm founded in 2003 by Arie and Rebecka Belldegrun, specializing in building and investing in innovative life science companies across biotech, pharma, and healthcare infrastructure. It is not a therapeutics developer itself, but rather a venture builder that has launched or co-founded major biotech firms (e.g., Kite Pharma, Allogene Therapeutics), a leading life sciences venture capital fund (Vida Ventures), a pioneering life sciences real estate developer (Breakthrough Properties, JV with Tishman Speyer), and a specialized credit financing firm (Symbiotic Capital).

Bellco Capital invests in therapeutics covering oncology (especially cell therapy), immunotherapy, and gene therapy, with its most notable portfolio companies spanning modalities such as CAR-T cell therapy, gene therapy (AAV), bispecific monoclonal antibodies, and others. However, clinical stages, indications, and modalities must be attributed to its portfolio companies, not Bellco Capital itself.

Bellco has no trading symbol, is not public, and does not report revenues. It maintains its headquarters in Los Angeles, California. Key people include Arie Belldegrun (Chairman/co-founder) and Rebecka Belldegrun (co-founder); partnerships include Tishman Speyer, Two River, and Vida Ventures. Its subsidiary and affiliate activities are concentrated in company creation, venture investing, credit provision, and life science infrastructure development.

Bellco Capital demonstrates a unique ecosystem-building model, supporting life science entrepreneurship across company formation, venture funding, real estate infrastructure, and alternative financing.